What is it about?
Evidence based narrative review of betrixaban for prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE
Featured Image
Why is it important?
Written for formulary committees. New Factor Xa inhibitor
Perspectives
only oral factor Xa inhibitor approved for this indication
Danial Baker
Washington State University
Read the Original
This page is a summary of: Formulary Drug Review: Betrixaban, Hospital Pharmacy, November 2017, SAGE Publications,
DOI: 10.1177/0018578717739397.
You can read the full text:
Contributors
The following have contributed to this page
